Interaction in cardiovascular crossover studies: the standard and the clinical analysis.
The crossover trial, which is considered the most powerful means of determining the efficacy of cardiovascular drugs, is frequently biased by treatment-by-period interactions. A second problem is that the standard analysis (Hills-Armitage analysis) for these biases is unreliable because of a low sensitivity. The author recently introduced an alternative method for the detection of interaction bias entitled the clinical analysis, because it looks at the clinical performance of the separate treatment groups in a trial and not, as in the standard analysis, at the means of the groups. In a mathematical model this analysis was capable of detecting interaction at a 30% lower level than the standard analysis. The present study was undertaken to show not only that the clinical analysis performs better than the standard but also that it enables the investigator to differentiate among different types of interactions, eg, physical carryover effect, rebound phenomenon, and psychological carryover effect.
Cleophas
T J
TJ
Department of Medicine, Merwede Hospital Sliedrecht-Dordrecht, The Netherlands.
D015982:Bias; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D003627:Data Interpretation, Statistical; D006801:Humans; D008962:Models, Theoretical; D016032:Randomized Controlled Trials as Topic; D012107:Research Design
D002317:Cardiovascular Agents